# TLX591 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tlx591

> TLX591, sponsored by Telix Pharmaceuticals Ltd (TLX): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TLX591 |
| Codes | TLX591 |
| Sponsor | Telix Pharmaceuticals Ltd (TLX) https://sec-api.dev/companies/tlx/catalysts |
| Indications | [metastatic castration resistant prostate cancer](https://sec-api.dev/indications/metastatic-castration-resistant-prostate-cancer) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jan 2022: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-02-24, last confirmed 2025-02-24.
- SEC Form 10-K (accession 0001140361-25-005562): "We dosed the first patient in a Phase 1 trial evaluating the safety and tolerability profile of TLX591 in combination with the standard of care in mCRPC patients in January 2022, which we refer to as the ProstACT SELECT trial." https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm

### December 7, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 3. Indication: metastatic castration resistant prostate cancer.
- First seen 2025-12-08, last confirmed 2026-02-19.
- Press release filed with the SEC (EX-99) (accession 0002007191-25-000073): "Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosopatamab tetraxetan) in patients with metastatic castration resistant prostate cancer (mCRPC)." https://www.sec.gov/Archives/edgar/data/2007191/000200719125000073/prostactpr.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "We dosed the first patients in Part 2 in Australia in December 2025, and are actively dosing patients at multiple clinical trial sites outside the U.S. This is the first Phase 3 trial to evaluate TLX591-Tx in combination with the standard of care (androgen receptor pathway inhibition or docetaxel) compared to the standard of care alone." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tlx591.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TLX591 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tlx591

```bibtex
@misc{secapidev_pdufa_tlx591_20261116,
  title        = {TLX591 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tlx591}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tlx591_20261116","title":"TLX591 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tlx591","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
